After ASM I sold 1/3 of my holdings at small profit to reduce my exposure and invest in another newly found biotech - that seems multibagger with 3-4 catalyst in H2-2016.
I think the good news/catalyst are not near so I am ready to sacrifice some profit - once the good news comes out I will buy again. In my view r/s and uplisting will be next big catalyst. Start of monotherapy may not move the SP that much.